GlassScriptPhysician profile
Rawa Sarji
NPI 1396978128
$2,272.63
in general payments reported to CMS, 2019-2025
30 companies · $402 in 2025
The $402 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $326 · 2020: $169 · 2021: $25.96 · 2022: $224 · 2023: $499 · 2024: $627 · 2025: $402.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,528.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,527.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $290.18 | 2019-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $285.82 | 2022-2025 | |
| Edwards Lifesciences Corporation | $192.60 | 2023-2025 | Sapien 3 Ultra Resilia |
| Abbott Laboratories | $166.32 | 2022-2023 | Mitraclip |
| Astrazeneca Pharmaceuticals LP | $146.99 | 2019-2025 | Farxiga, Wainua, Lokelma |
| Janssen Pharmaceuticals, INC | $144.62 | 2019-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $141.94 | 2019-2024 | Eliquis, Camzyos |
| Biotronik INC. | $111.76 | 2019-2021 | |
| Pfizer INC. | $87.84 | 2023-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $69.95 | 2019-2020 | |
| Actelion Pharmaceuticals US, INC. | $69.85 | 2019 | |
| Amgen INC. | $63.70 | 2020-2024 | Repatha |
| Cvrx, INC. | $61.04 | 2024 | Barostim Neo System |
| Scpharmaceuticals INC. | $50.99 | 2024-2025 | |
| Kiniksa Pharmaceuticals International, Plc | $44.66 | 2024 | Arcalyst |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $39.65 | 2020-2023 | Verquvo |
| Kiniksa Pharmaceuticals, LTD. | $35.54 | 2023 | Arcalyst |
| Inspire Medical Systems, INC. | $35.14 | 2024-2025 | Inspire |
| Sanofi-Aventis U.S. LLC | $32.89 | 2019-2023 | |
| Impulse Dynamics (USA) INC. | $26.79 | 2024 | Optimizer |
| Lexicon Pharmaceuticals, INC. | $22.86 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $21.78 | 2024 | Evkeeza |
| Boston Scientific Corporation | $20.55 | 2025 | Watchman Flx |
| Amarin Pharma, INC. | $19.44 | 2020 | |
| Alnylam Pharmaceuticals INC. | $19.03 | 2025 | Amvuttra |
| Novo Nordisk INC | $15.17 | 2025 | Ozempic |
| Mylan Specialty L.P. | $15.08 | 2019 | |
| Mallinckrodt Hospital Products INC. | $14.85 | 2020 | |
| Bridgebio Pharma, INC. | $14.80 | 2025 | Attruby |
| Mallinckrodt Enterprises LLC | $10.80 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rawa Sarji listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.